Breast cancer treatment: Drug Kisqali approval expanded for ... - NBC News
WEB2 days ago · The drug was found to reduce the risk of a patient's breast cancer coming back by 25%. The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to ...
FDA approves Novartis Kisqali® to reduce risk of recurrence in …
WEB2 days ago · Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhibitor adjuvant therapy 1,2; Kisqali ...
FDA Approves Adjuvant Ribociclib Plus AI Therapy for HR+, HER2- Breast …
WEB2 days ago · The FDA approved adjuvant ribociclib (Kisqali) plus an aromatase inhibitor (AI) for patients with hormone receptor (HR)–positive, HER2-negative stage II and III early breast cancer that has a high risk of recurrence, including those with node-negative disease, according to an announcement from Novartis, the manufacturer of ribociclib. 1 The approval is based on data from the phase 3 NATALEE ...
FDA approval of new drug regimen helps reduce risk of breast cancer ...
WEB3 days ago · This type of breast cancer is the most common subtype of the disease, accounting for nearly 70% of breast cancer cases in the United States. Current treatment includes endocrine therapy — which blocks or lowers the levels of estrogen production so cancer cells can't use it to grow and spread — but there is still a …
New study finds triple-negative breast cancer tumors with an …
WEBApr 25, 2024 · A new multicenter, international study suggests that people who have early-stage triple-negative breast cancer (TNBC) and high levels of immune cells within their tumors may have a lower risk of recurrence and better survival rates even when not treated with chemotherapy.
Breast cancer - Latest research and news | Nature
WEBBreast cancer articles from across Nature Portfolio. Breast cancer is caused by the development of malignant cells in the breast. The malignant cells originate in the lining of the milk...
Estrogen a more powerful breast cancer culprit than we realized
WEBMay 17, 2023 · A Harvard Medical School study shows the sex hormone estrogen — thus far thought to be only a fuel for breast cancer growth — can directly cause tumor-driving genomic rearrangements.
Breast Cancer Drug Trial Results in ‘Unheard-Of’ Survival
WEBJun 7, 2022 · The clinical trial, sponsored by the pharmaceutical companies Daiichi Sankyo and AstraZeneca and led by Dr. Shanu Modi of Memorial Sloan Kettering Cancer Center, involved 557 patients with...
Targeting HER2-positive breast cancer: advances and future …
WEBNov 7, 2022 · The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading...
Enhertu Effective in HER2-Positive Metastatic Breast Cancer
WEBOct 19, 2021 · In people with metastatic HER2-positive breast cancer, the targeted drug trastuzumab deruxtecan (Enhertu) markedly lengthened progression-free survival compared with trastuzumab emtansine (Kadcycla), new study results show.
- Some results have been removed
Skip to content